DexCom, which makes continuous glucose monitoring (CGM) systems for diabetes management, announced its second-quarter results after the market closed on Tuesday, and there was plenty of good news for investors.Perhaps the only question for the healthcare stock is how increased competition from Abbott Laboratories' recently approved FreeStyle Libre 2 integrated CGM system will impact G6 sales.